
|Articles|August 1, 2003
Intravitreal triamcinolone shows promise for CRVO
Fort Lauderdale, FL-Intravitreal injection of triamcinolone acetonide (Kenalog, Bristol-Myers Squibb) may be a safe and effective treatment for central retinal vein occlusion (CRVO), said Michael S. Ip, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
SpyGlass Pharma releases positive data from 2 trials of Bimatoprost Drug Pad-IOL System
2
Beyond the surface: Tackling complex dry eye cases
3
Redefining glaucoma care: Where innovation meets clinical insight
4
An Extreme Case of Demodex Blepharitis: From Misdiagnosis to Remarkable Recovery
5



















































.png)


